Print

IAVI V002

A Phase 2, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk f

Trial Details:

II Withdrawn
International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID)
VRC-HIVDNA016-00-VP,VRC-HIVADV014-00-VP DNA env A, env b, env C, gag B, pol B, nef B; Ad5 env A, env B, env C, gag B, pol B
VRC-HIVDNA016-00-VP DNA
VRC-HIVADV014-00-VP Viral Vector - Adeno
Kenya, Rwanda, Uganda, Zambia 0
http://clinicaltrials.gov/ct/show/NCT00415649?order=19